The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04338399 |
Recruitment Status :
Active, not recruiting
First Posted : April 8, 2020
Last Update Posted : November 2, 2023
|
Sponsor:
Adlai Nortye Biopharma Co., Ltd.
Information provided by (Responsible Party):
Adlai Nortye Biopharma Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | June 30, 2025 |
Estimated Study Completion Date : | June 30, 2026 |